¾«¶«Ó°Òµ

Source:

Long-term research that was initiated at UCLA’s Jonsson ComprehensiveÌýÌýCenter on lymphatic mapping and sentinel-nodeÌý, techniques for detecting the earliest spread () ofÌý, the deadliest form ofÌý, has confirmed that these techniques significantly prolong patients’ disease-free and melanoma-specific survival over the traditional observational “watch and wait” techniques.

This affirms a new standard for detecting melanoma metastasis to theÌýÌýby allowing doctors to quickly determine which patients actually have nodal metastasis and may benefit from having their non-sentinel lymph nodes removed (approximately 20% of patients), while sparing the surgery and its associated complications and substantial cost for the many patients who it cannot benefit (approximately 80% of patients).

Led by the late Dr. Donald L. Morton, former UCLA professor of surgery and director of the in Santa Monica and Dr. Alistair J. Cochran, professor in the departments of surgery andÌýÌýand laboratory medicine at the David Geffen School of Medicine at UCLA, the study was published February 13, 2014 in the New England Journal of Medicine, and evaluated outcomes of 2001 melanoma patients at 10 years of follow-up. The results confirm that lymphatic mapping and sentinel-node biopsy represent an advantageous change in practice for doctors treating melanoma patients.

One important long-term finding was that the thickness of the initialÌýÌýtumor relates to the effectiveness of these treatments in managing nodal and other metastases. Patients with primary melanoma tumors of intermediate thickness (1.20 to 3.5 millimeters thick) who had sentinel-node biopsies with immediate complete removal of the lymph nodes if the sentinel node contained cancer cells had an overall disease-free survival of 71.3% compared with 64.7% for those whose nodes were observed without sentinel biopsy. The research also found that sentinel-node biopsy prolonged distant disease-free survival (survival without disease spread to distant organs such asÌý, lungs, or liver) and melanoma-specific survival (survival without development of additional metastases) for patients with lymph node metastasis from primaryÌýÌýof intermediate thickness.
20% of patients with melanoma have…